Cancer
-
Randomized Controlled Trial Multicenter Study
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Epidermal growth factor receptor (EGFR, HER-1, and erbB1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. ⋯ In patients who had metastatic breast cancer, decreased serum EGFR/normal serum HER-2 predicted shorter survival compared with patients who had normal levels of serum EGFR/HER-2. This patient subgroup deserves further study to assess their response to and selection for anti-EGFR-directed therapies.